Gambogic acid induces apoptosis in diffuse large B-cell lymphoma cells via inducing proteasome inhibition

Xianping Shi, Xiaoying Lan, Xin Chen, Chong Zhao, Xiaofen Li, Shouting Liu, Hongbiao Huang, Ningning Liu, Dan Zang, Yuning Liao, Peiquan Zhang, Xuejun Wang, Jinbao Liu

Research output: Contribution to journalArticlepeer-review

14 Scopus citations

Abstract

Resistance to chemotherapy is a great challenge to improving the survival of patients with diffuse large B-cell lymphoma (DLBCL), especially those with activated B-cell-like DLBCL (ABC-DLBCL). Therefore it is urgent to search for novel agents for the treatment of DLBCL. Gambogic acid (GA), a small molecule derived from Chinese herb gamboges, has been approved for Phase II clinical trial for cancer therapy by Chinese FDA. In the present study, we investigated the effect of GA on cell survival and apoptosis in DLBCL cells including both GCB- and ABC-DLBCL cells. We found that GA induced growth inhibition and apoptosis of both GCB- and ABC-DLBCL cells in vitro and in vivo, which is associated with proteasome malfunction. These findings provide significant pre-clinical evidence for potential usage of GA in DLBCL therapy particularly in ABC-DLBCL treatment.

Original languageEnglish (US)
Article number9694
JournalScientific reports
Volume5
DOIs
StatePublished - Apr 13 2015

ASJC Scopus subject areas

  • General

Fingerprint Dive into the research topics of 'Gambogic acid induces apoptosis in diffuse large B-cell lymphoma cells via inducing proteasome inhibition'. Together they form a unique fingerprint.

Cite this